Voyager Therapeutics, Inc. (NASDAQ:VYGR) Receives $13.75 Consensus Price Target from Analysts

Shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR) have received an average recommendation of “Moderate Buy” from the six brokerages that are covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation and five have issued a buy recommendation on the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $13.75.

A number of analysts have recently weighed in on the company. HC Wainwright cut their target price on Voyager Therapeutics from $30.00 to $25.00 and set a “buy” rating for the company in a research report on Wednesday, November 12th. Wedbush reaffirmed an “outperform” rating and set a $8.00 price objective on shares of Voyager Therapeutics in a research report on Tuesday, November 11th. Finally, Wall Street Zen upgraded shares of Voyager Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, November 15th.

Voyager Therapeutics Trading Up 0.6%

NASDAQ VYGR opened at $3.41 on Friday. The company has a market cap of $189.60 million, a price-to-earnings ratio of -1.58 and a beta of 1.30. The company has a 50 day moving average of $3.95 and a 200-day moving average of $4.10. Voyager Therapeutics has a 1-year low of $2.64 and a 1-year high of $5.55.

Insider Activity

In other Voyager Therapeutics news, CEO Alfred Sandrock sold 12,192 shares of the business’s stock in a transaction that occurred on Tuesday, February 10th. The shares were sold at an average price of $3.78, for a total transaction of $46,085.76. Following the completion of the transaction, the chief executive officer directly owned 509,989 shares in the company, valued at $1,927,758.42. The trade was a 2.33% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In the last quarter, insiders have sold 20,286 shares of company stock worth $77,248. Company insiders own 4.53% of the company’s stock.

Hedge Funds Weigh In On Voyager Therapeutics

A number of institutional investors have recently modified their holdings of VYGR. Bank of Montreal Can bought a new stake in shares of Voyager Therapeutics during the 2nd quarter worth $36,000. Wexford Capital LP acquired a new position in Voyager Therapeutics during the third quarter worth about $42,000. ProShare Advisors LLC bought a new position in shares of Voyager Therapeutics in the fourth quarter worth about $44,000. CIBC Asset Management Inc acquired a new stake in shares of Voyager Therapeutics in the 4th quarter valued at approximately $45,000. Finally, R Squared Ltd bought a new stake in shares of Voyager Therapeutics during the 2nd quarter valued at approximately $48,000. Institutional investors and hedge funds own 48.03% of the company’s stock.

About Voyager Therapeutics

Voyager Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of gene therapies for serious neurological diseases. The company’s core activities center on the design and delivery of engineered adeno-associated viral (AAV) vectors tailored to target cells in the brain and central nervous system. Through its proprietary CapsidMap and VectorMap platforms, Voyager aims to enhance vector potency, specificity and durability to address diseases with high unmet medical need.

The firm’s pipeline includes several AAV-based candidates in preclinical and early clinical development.